N-tert-Butyl-nortropinon | 62028-30-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: N-tert-Butyl-nortropinon
• 英文别名: 8-tert-butyl-nortropan-3-one；8-Tert-butyl-8-azabicyclo[3.2.1]octan-3-one
• CAS: 62028-30-2
• 化学式: C₁₁H₁₉NO
• 分子量: 181.278
• InChiKey: IWSMBQGLMBANFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Griffith A. David

  公开号：US20070275964A1

  公开（公告）日：2007-11-29

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了化学式为(I)的化合物，它们作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中的用途。
• IMIDAZOTRIAZINONE COMPOUNDS
  申请人：Ripka Amy

  公开号：US20120157458A1

  公开（公告）日：2012-06-21

  The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

  本发明提供了咪唑三唑酮类化合物，这些化合物是磷酸二酯酶9的抑制剂。本发明还提供了制备这些化合物的方法、药物组成物、制药制剂以及在哺乳动物中（包括人类）治疗与PDE9相关的疾病或紊乱的药物用途。
• 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS
  申请人：Ripka Amy

  公开号：US20110183976A1

  公开（公告）日：2011-07-28

  5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.

  本文描述了一些5-和6-成员杂环化合物，它们是磷酸二酯酶10的抑制剂，以及这些化合物的制备方法、制药组合物、制药制剂和在治疗哺乳动物，包括人类的中枢神经系统(CNS)疾病和其他可能影响CNS功能的疾病中使用这些化合物的制药用途。此外，本文还描述了治疗神经、神经退行性和精神疾病，包括但不限于认知缺陷或精神分裂症状的治疗方法。
• 1,2-Disubstituted Heterocyclic Compounds
  申请人：Ripka Amy

  公开号：US20100137317A1

  公开（公告）日：2010-06-03

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  本文描述了抑制磷酸二酯酶10的1,2-二取代杂环化合物。同时还描述了这些化合物的制备过程、制药组合物、制药制剂以及在治疗哺乳动物（包括人类）的中枢神经系统（CNS）疾病和其他可能影响CNS功能的疾病中的制药用途。可治疗的疾病包括神经、神经退行性和精神障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。